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Summary 
Cisplatin (DDP) is a chemotherapeutic agent that has shown efficacy against primary CNS malignancies. Intra- 
arterial (IA) administration of DDP to patients with brain tumors should produce higher peak levels of drug 
than intravenous (IV) administration of  an identical dose and reduce systemic toxicity. Twelve patients with 
malignant glioma were entered into the study. All had failed irradiation, 11 had failed IA BCNU. Each patient 
received IA DDP, 58-100 mg/m 2, into the internal carotid artery at four to six week intervals. One of  12 pa- 
tients had a partial response of 6 months. The remaining 11 patients had progressive disease [10] or severe com- 
plications [1]. Toxicity included seizures in four patients, weakness and/or  aphasia in four patients, coma in 
two patients, and visual deterioration in two patients. IA DDP has very limited efficacy in patients with malig- 
nant gliomas after failure of  nitrosoureas and is associated with an unacceptable level of  toxicity. IA DDP 
may be more effective when used as initial chemotherapy of  malignant gliomas. 
Introduction 
Primary central nervous system (CNS) malignancies 
continue to have a high mortality. Approximately 
one-half of these cases are malignant gliomas which 
are classified as glioblastoma multiforme (Kerno- 
han' s grade IV) and anaplastic astrocytoma (Kerno- 
han's grade III) [1]. Malignant gliomas are uniform- 
ly fatal tumors. Studies by the Brain Tumor Study 
Group [2] have shown a median survival of  17 weeks 
in patients who have received only surgical resection. 
Survival was extended to a median of 37 weeks with 
radiation therapy (RT). The additional of  single- 
agent chemotherapy has improved long term sur- 
vival to a limited extent. BCNU, when used after 
resection and RT, improved the median survival to 
51 weeks [3] in one trial and 50 weeks in another [4]. 
In recent years newer methods of administration 
have been sought. Craft et al. [5] compared 14C- 
labelled BCNU given IV and IA in monkeys and 
found IA administration produced a four-fold 
higher brain drug level than IV administration of the 
same dose. These and subsequent studies sug- 
gested that IA administration could potentially 
reduce systemic toxicity [6]. Cisplatin (cisdi- 
chlorodiammineplatinum; DDP) is an inorganic 
complex formed by an atom of  platinum (II) sur- 
rounded by chlorine and ammonia atoms in the cis 
position of  the horizontal plane. DDP has an- 
titumor effect in a wide variety of neoplasms, espe- 
cially testicular [7], bladder [8], ovarian [9], and 
head and neck tumors [10]. The mode of action of 
DDP appears to be direct binding to DNA, forming 
intrastrand and interstrand cross links between gua- 
nine residues [11]. 
DDP has also been shown to be effective against 
primary CNS malignancies. Initial studies by Kahn 
et al. [12] and Levanthal and Freeman [13] using IV 
DDP were encouraging. Stewart et al. [14] studied IA 
administration of DDP in patients with glioblasto- 
ma multiforme and metastatic tumors. Six of their 
10 evaluable patients responded to treatment. They 
were able to demonstrate that IA infusion of  DDP 
(60 mg/m 2 q6 wks) via transfemoral selective inter- 
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al carotid artery catheterization was technically 
feasible and capable of producing tumor regression 
or stabilization. Subsequent studies using IA DDP 
have also shown encouraging results against primary 
CNS tumors [15-18]. This report describes our ex- 
perienc using IA DDP in the treatment of patients 
with malignant gliomas. 
Materials and methods 
Twelve patients were entered into the study. Patient 
characteristics are listed in Table 1. Prior to entry all 
patients had had at least one subtotal resection, and 
all had pathological confirmation of their diagnosis. 
Nine patients had glioblastoma multiforme or 
anaplastic astrocytoma (grade III or IV astrocyto- 
ma). The remaining patients had gliosarcoma, grade 
II/II1 astrocytoma/oligodendroglioma, and epen- 
dymoma, respectively. These tumors were all 
unilateral and confined to the left or right internal 
carotid arterial distribution. The average age was 43 
years with a range of 11-62 years. All patients had 
received between 5400-6600 rads of radiation prior 
to this study. Eleven of 12 patients had received prior 
chemotherapy. All 11 had received IA BCNU. Two 
had received continuous infusion of IA dich- 
loromethotrexate (DCMTX). One each had received 
IA diaziquone (AZQ), continuous IA flourodeoxyu- 
ridine (FUdR), and IV dacarbazine (DTIC). One pa- 
tient also received vincristine and procarbazine. 
Nine of the 12 patients were taking stable doses of 
Table 1. Patient characteristics 





Mean age in yrs. (range): 43 (11 - 62) 
Mean Karnofsky score at entry (range): 80 (50 -90 )  
Prior chemotherapy 
BCNU 11 
D C M T X  2 
Other 4 
None 1 
dexamethasone at the time of entry into the study. 
Doses ranged from 2 to 16 mg/day, with an average 
dose of 8 mg/day. Each patient showed evidence of 
progressive disease by cranial computed tomogra- 
phy (CT) criteria and/or neurologic examination 
prior to inclusion in this study. Each patient was in- 
formed of the investigational nature of the study and 
signed a consent form. 
Pretreatment evaluation consisted of history and 
physical examination including a complete neuro- 
logic examination, Karnofsky rating, and CT scan 
with and without contrast. CBC with differential, 
platelet count, electrolytes, BUN, creatinine, creati- 
nine clearance, SGOT, alkaline phosphatase, and 
LDH were obtained. Baseline audiograms were per- 
formed on all patients. 
During treatment each patient had weekly CBC 
with differential and platelet counts. Bimonthly 
each patient received a neurologic examination and 
Karnofsky rating. Audiograms were repeated every 
12 weeks. The pretreatment laboratory battery was 
repeated prior to each subsequent treatment. 
Prior to administration of IA DDP, each patient 
received hydration with D5 0.45% NaCL at 
150 cc/hr for 12 hours. Dexamethasone 50 mg IV 
was given the night before DDP adminstration. It 
was repeated along with mannitol 12.5 Gm IV the 
morning of DDP administration. DDP (Bristol 
Laboratories) was dispensed for IA use in the form 
of lyophilized powder in 10 mg vials. It was recon- 
stituted for IA use by dissolving 58-100 mg/m 2 in 
175 to 200 ml of 0.45% NaCL solution. Heparin 
(1000 units) was added to each infusion. The DDP 
was infused into the left or right internal carotid ar- 
tery via a catheter placed percutaneously using the 
femoral approach (10 patients) or through the side- 
port of an Infusaid permanently implantable in- 
tracarotid drug delivery system (manufactured by 
Shiley Infusaid Corp., Norwood, MA) (2 patients). 
The Infusaid pump had been implanted prior to en- 
try this study using a technique described by Phillips 
etal. [19]. An IMED 960 (Medical electronics Corp.) 
infusion pump was used to infuse DDP through the 
catheter over one hour. A hyperalimentation filter 
was in place between the DDP solution and the fem- 
oral catheter. In all infusions, the catheter was below 
the ophthalmic artery. After infusion, each patient 
was hydrated with D5 0.45% NaCL at 200 cc/hr for 
12 hours. Urine output  was monitored closely. I f  it 
dropped below 200 cc/hr, mannitol 12.5 Gm IV was 
given. Metoclopramide and lorazepam were ad- 
ministered as needed for nausea and vomiting. Treat- 
ment was repeated at 4-6  week intervals as long as 
the patient remained stable or improved and had ab- 
solute granulocyte counts greater than 2500 and 
platelet counts greater than 100000. 
Response criteria were as follows: Complete Re- 
sponse - complete resolution of all abnormalities on 
CT scan and an improved or normal neurologic ex- 
aminat ion without steroid medication; Partial Re- 
sponse - a decrease in the size of  the measurable 
mass lesion on CT scan plus a stable or improved 
neurologic examination on stable or decreasing 
doses of  steroids; Stable Disease - no change in the 
size of  the tumor  on CT scan without significant 
change in neurologic examination on stable or 
decreasing doses of  steroids; Progressive Disease - 
increase in the size of  the tumor  on CT scan and/or  
progressive worsening of  neurologic function direct- 
ly attributable to the growth effects of  the tumor. 
The duration of response dated from the onset of  
treatment until demonstration of disease progres- 
sion. A complete trial consisted of  at least two infu- 
sions of  DDR The trial was stopped after one infu- 




Twelve patients received a total of  24 IA DDP infu- 
sions. Patient response characteristics are listed in 
Table 2. Eighteen of 24 infusions were at a dosage 
of 75 m g / m  2. Other doses were as follows: one at 
58 m g / m  2, three at 9 0 m g / m  2, and two at 
100 m g / m  2. Five patients received one course of  
DDP, four patients received two courses, two pa- 
tients received three courses, and one patient 
received five courses o f DDP. The cumulative dosage 
ranged from 140 to 580 mg, with an average of  
266 mg. 
Only one of  12 patients (8°70) demonstrated a re- 
sponse to IA DDP. There were no complete 
responders. Patient #3 who had a left frontoparietal 
grade I I - I I I  astrocytoma/oligodendroglioma, and 
had not responded to prior BCNU, had a partial re- 
sponse for six months during which time she 
received three more treatments. After her second 
treatment with DDP her tumor  displayed 
diminished bulk and mass effect by CT. During that 
time she was clinically stable. Repeat CT scan subse- 
quently showed slightly increased volume and en- 
hancement. Ten of  the remaining 11 patients had 
progressive disease. Five patients demonstrated both 
CT and clinical progression. Four patients had sta- 
ble CT examination but progressed clinically. Clini- 
cal progression was manifested by worsening mono-  
Table 2. Response characteristics 
Pat ient  DDP # Cumulative 
dose treatments dose (mg) 
(mg) 
Overall Clinical CT Time to 
response failure 
(mo) 
1 75 2 335 
2 75 3 405 
3 75 5 580 
4 90 3 330 
5 58/75 2 245 
6 75 1 140 
7 75 1 145 
8 75 1 130 
9 75 2 272 
10 75 1 150 
11 75/100 2 265 
12 100 1 200 
P P S 4 
P P S 4 
R S R 6 
P S P 4 
P P P 4 
P P P 3 
P P S 1.5 
P P P 1.5 
P P S 3 
P P P 1 
P P P 3.5 
C C S 1? 
Abbreviations:  R - partial  response; S - stable; P - progression; C - complications 
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or hemiparesis in five patients, progressive aphasia 
in six patients, increased seizure frequency in two pa- 
tients, and progressive headache in two patients. 
One patient had a stable clinical exam but had CT 
progression. The last patient's (patient #12) tumor 
was stable by CT criteria but developed complica- 
tions from the DDP infusion including mental status 
changes and encephalopathy that progressed to 
coma. The range of  time to treatment failure was one 
to six months. The average time to treatment failure 
was 3.0 months. 
Toxicity data are listed in Table 3. The most fre- 
quent acute toxicity was gastrointestinal. Seven of 
our twelve patients developed symptoms of nausea 
and vomiting. These symptoms were transient, clear- 
ing after 24 hours, although they did require treat- 
ment with antiemetics. Three patients experienced 
mild myelosuppression with WBC reaching nadirs 
of  2500, 2500, and 2400, respectively. All platelet 
count nadirs remained above 125000. None of  our 
patients developed renal toxicity, hypomagnesemia 
or diminished auditory acuity. 
Two patients exhibited retinal toxicity with as- 
sociated decreased visual acuity of the ipsilateral eye. 
Patient #1 complained of pain in his left eye during 
and after his initial DDP infusion. He subsequently 
lost visual acuity and became blind in that eye. 
Ophthalmic examination and fluorescein angiogra- 
phy revealed retinal vasculitis. Patient #3 had no pain 
during DDP infusion but developed blurred vision 
and diminished visual acuity after her second treat- 
ment. 
The remaining toxicity was referable to the CNS. 
Three patients had acute seizure activity during infu- 
sion of  DDP. Patients #6 and 10 exhibited brief spon- 
taneously resolving simple partial seizures of  the 
arm, and arm and leg, respectively, contralateral to 
the side of infusion. Patient #2 developed status 
epilepticus which progressed to an encephalopathic 
and then comatose state. She died four weeks after 
her initial infusion. CT scans during this time were 
unchanged. 
Four patients developed weakness and/or  apha- 
sia. Patient #3 acutely developed expressive aphasia 
after her second infusion which never completely re- 
solved. Patient #6 developed an acute complex of 
signs three days after treatment that included in- 
creased hemiparesis, seizure activity, and aphasia. 
He progressed to an encephalopathic state, followed 
by coma, which lasted for two weeks. He eventually 
recovered alertness but was left with a dense right 
hemiparesis and severe expressive aphasia. Patient 
#9 acutely developed aphasia and right arm weak- 
ness that resolved after 12 hours. Patient #10 acutely 
developed right hemiparesis that never returned to 
baseline after months of follow-up. One patient de- 
veloped trigeminal mononeuropathy manifested by 
numbness of the face ipsilateral to the side of her in- 
fusion. This developed after her fourth treatment. 
Table 3. Toxicity 




Motor weakness 3 
Impaired speech 3 










The theoretical advantages of administering a 
chemotherapeutic agent IA instead of  IV have been 
examined by previous authors [6, 20]. The regional 
advantage R d is defined as the ratio of tumor ex- 
posure with IA administration to that with IV ad- 
ministration, where exposure is the concentration- 
time integral. Assuming linear kinetics of  drug dis- 
tribution and metabolism it can be shown that Rd is 
independent of the rate of drug administration. As- 
suming clearance by the lungs is negligible: 
CL(tb) 
R d = l +  
F 
where F is flow in the artery infused (L/min), and 
CL(tb) is the total body metabolic clearance of the 
drug (L/min) [20]. It is apparent from this relation- 
ship that R a for a given drug can be maximized by 
low flow in the artery infused and by rapid systemic 
clearance of  the drug. Ra for BCNU has been meas- 
ured in squirrel monkeys [21]. IA administration in- 
creased the total tissue radioactivity by 2.4-2.7 and 
the DNA bound fraction (presumed site of action of 
BCNU) by 2.3-2.7. These values approximate the 
calculated R d for BCNU in humans of 3.7 based on 
an internal carotid blood flow of 0.25 L/min and a 
plasma clearance of  0.7 L/min. 
Based on available clearance data for DDP, R d 
can be calculated. Data from Campbell et aL [22] 
show a total body clearance rate for DDP of  approxi- 
mately 0.365 L/min. If unilateral internal carotid 
artery blood flow is estimated to be 0.25 L/rain, 
then R d is calculated to be 2.46. Based on this infor- 
mation, an advantage for IA therapy was postulated 
and formed the rationale for administering DDP IA 
in our study. A recent study using positron emission 
tomography (PET) analysis of DDP adminstration 
estimated R a to be 2.5 [23]. This measured value 
closely approximates our calculated value of  Rd. 
In our study, none of  our patients had a complete 
response. One of 12 had a brief partial response. She 
had a grade II-III astrocytoma/oligodendroglioma. 
Recent data from Cairncross and Macdonald [24] 
suggests that oligodendrogliomas are quite 
chemosensitive. Her partial response may have been 
from this fraction of tumor. The efficacy of  IA DDP 
was less than that seen in most other trials of IV [12, 
13] or IA [14-18] administered DDP. Our response 
rate was also considerably less than those obtained 
with IV BCNU [3, 4]. Possible explanations for our 
low response rate may be related to the fact that in 
our study 92% of our patients had failed IA BCNU 
therapy. A higher percentage of our patients failed 
previously chemotherapy than in other studies. The 
BCNU may have selectively killed clones of  cells that 
would have been sensitive to DDP, allowing repopu- 
lation with more resistant cells [25, 26]. In vitro 
studies comparing cross-resistance between alkylat- 
ing agents showed significant cross-resistance be- 
tween BCNU and DDP [27]. It is therefore possible 
that IA DDP would be more efficacious when used 
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with patients who have not received prior IA BCNU 
chemotherapy. Ongoing research at our institution 
does suggest that procarbazine may be an effective 
agent when used to treat patients after failure of IA 
BCNU (unpublished data). A further possible expla- 
nation for our lack of  partial responders may be that 
our treatment interval was too long. By using shorter 
intervals, more partial responses may have been 
seen, but this probably would have resulted in fur- 
ther toxicity. The high pre-treatment doses of  dex- 
amethasone used theoretically could have affected 
the blood-brain barrier and decreased the amount of 
DDP delivered to the tumor. High pre-treatment 
doses of dexamethasone could have also increased 
tumor concentrations of metallothionein (MT), an 
inducible low molecular weight protein that binds 
heavy metal compounds, including platinum, and 
affords resistance to DDP [28, 29]. However, recent 
in vitro data in rat hepatocytes showed that after ini- 
tial MT induction by steroids, further increments in 
dosage or length of  treatment did not significantly 
increase MT concentrations [28]. Therefore, since 
our patients were on chronic doses of  dexametha- 
sone, the effects of additional steroid on MT induc- 
tion were probably negligible. 
We doubt that our response rates were com- 
promised because of the DDP doses administered. 
Data from several studies showed that at least 
60 mg/m 2 of  IA DDP was adequate to achieve a re- 
sponse [14-16]. All but one of  our patients received 
75-100 mg/m 2 of DDP per dose. 
An additional patient not included in our study 
with metastatic squamous cell carcinoma to the base 
of skull and parasellar region was an unequivocal 
responder. She received six treatments with IA DDP 
at a dose of 75 mg/m 2. Clinically she remained sta- 
ble while CT scan showed shrinkage of her tumor. 
This partial response lasted for seven months. She 
then developed increased tumor mass by CT. 
The major dose limiting toxicity in our study was 
neurotoxicity. None of our patients developed severe 
toxicity of  the GI tract, kidneys, or bone marrow. 
Four of our patients experienced acute seizure activi- 
ty, one of  whom had status epilepticus requiring 
treatment. Seizures have been reported by other 
authors, but not as frequently as in our series [15, 
30]. Three patients experienced increased mono-or  
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hemiparesis. All had large tumors with significant 
enhancement and surrounding edema. Kapp and 
Sanford [31] theorize that gliomas, especially if near 
the internal capsule, could disrupt relatively the 
blood-brain barrier of  nearby normal neural tissue 
exposing it to toxic concentrations of DDP that 
could produce dysfunction. Our patients received 
aggressive post-treatment hydration which could 
have lead to an exacerbation of vasogenic edema to 
an already disrupted blood-brain barrier. An alter- 
native explanation is that these acute infusion- 
related complications represented thromboembolic 
events. Two patients each developed encephalopathy 
progressing to coma. This has also been documented 
by Feun et  al. [15]. One of these patients remained 
in coma until death while the other recovered after 
two weeks. The etiology of these catastrophic events 
and why it affected these patients in a differential 
fashion is unclear. 
To further clarify the CNS toxicity seen in our pa- 
tients, the role of prior BCNU was evaluated. The 
patients who had received prior BCNU and did not 
develop complications had a mean total dose of 
981 mg/m 2. The mean total dosage in patients who 
did develop complications was 1066 mg/m 2. This is 
not a significant difference and does not support a 
correlation between prior BCNU dosage and subse- 
quent development of  complications with IA DDP. 
A major dose-limiting toxicity in many studies has 
been retinal toxicity [15, 32]. In this study, one pa- 
tient developed a painless decrement in visual acuity 
after her second treatment. A second patient devel- 
oped pain and blurring of vision coincident with his 
initial DDP infusion that progressed to complete 
blindness. Recent attempts to avoid retinal toxicity 
by using supraophthalmic infusion techniques 
although initially promising, may increase CNS tox- 
icity [17, 33]. 
Ototoxicity has been a frequent complication of 
therapy in some studies [34, 35]. None of our pa- 
tients developed ototoxicity. An additional patient 
with metastatic squamous cell carcinoma, not in- 
cluded in this study, received IA DDP divided be- 
tween the left carotid and vertebral arteries and de- 
veloped moderately severe ototoxicity after her fifth 
treatment. It appears that the large cumulative doses 
of DDP, as well as infusion of  the drug via the 
posterior circulation, made this patient more vulner- 
able to ototoxicity. This patient also developed 
peripheral neuropathy as a consequence of DDP. 
She received cumulative DDP doses in excess of  
375 mg/m 2. Thompson et  al. [36] have reported 
that peripheral neuropathy becomes clinically ap- 
parent after a cumulative DDP dose of 350 mg/m 2. 
Our study corroborates their threshold dose. 
Although it is not clear whether the same mecha- 
nism is involved, our glioma patient with trigeminal 
mononeuropathy also had a cumulative DDP dose 
in excess of 350 mg/m 2. All other patients had cu- 
mulative doses less than 280 mg/m 2 and did not de- 
velop peripheral neuropathy. 
Conclusion 
IA administration of DDP has very limited efficacy 
in patients with primary malignant gliomas showing 
disease progression after proving refractory to 
nitrosourea therapy. In our study, only one of 12 pa- 
tients responded to IA DDP treatment. The DDP 
doses used in our study of  75 mg/m 2 or more 
resulted in an unacceptable level of  toxicity, especial- 
ly to the CNS. However, DDP may prove to be more 
effective when used as initial therapy. 
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